1-(5-甲基-2-吡啶基)哌嗪盐酸盐 | 1185307-85-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 1-(5-甲基-2-吡啶基)哌嗪盐酸盐
• 英文名称: 1-(5-methyl-2-pyridyl)piperazine hydrochloride
• 英文别名: 1-(5-Methylpyridin-2-yl)piperazine hydrochloride；1-(5-methylpyridin-2-yl)piperazine;hydrochloride
• CAS: 1185307-85-0
• 化学式: C₁₀H₁₅N₃*ClH
• 分子量: 213.71
• InChiKey: KKELTCOACYCGAZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.22
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  28.2
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  (1S,2S)-4-oxo-2-(thiophene-3-yl)cyclohexanecarboxylic acid 、 1-(5-甲基-2-吡啶基)哌嗪盐酸盐 在 1-羟基苯并三唑 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 为溶剂， 生成 (3S,4S)-4-(4-(5-methylpyridin-2-yl)piperazine-1-carbonyl)-3-(thiophen-3-yl)cyclohexan-1-one
  参考文献：
  名称：

  The discovery of potent antagonists of NPBWR1 (GPR7)

  摘要：

  The synthesis and evaluation of small molecule antagonists of the G protein-coupled receptor NPBWR1 (GPR7) are reported for the first time. [4-(5-Chloropyridin-2-yl)piperazin-1-yl][(1S,2S,4R)-4-{[(1R)-1-(4-methoxyphenyl)ethyl]amino}-2-(thiophen-3-yl)cyclohexyl]methanone (1) emerged as a hit from a high-throughput screen. Examination of substituents that focused on replacing the 5-chloropyridine and 4-methoxybenzylamino groups of 1 led to the identification of compounds that exhibited subnanomolar potencies as low as 660 pM (9k) in the functional assay and 200 pM in the binding assay (91). (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.11.126
• 作为产物：
  描述：

  4-(5-甲基吡啶-2-基)哌嗪-1-羧酸叔丁酯 在 盐酸 作用下， 以 1,4-二氧六环 为溶剂， 反应 3.0h， 以98%的产率得到1-(5-甲基-2-吡啶基)哌嗪盐酸盐
  参考文献：
  名称：

  WO2018125961A5

  摘要：

  公开号：

  WO2018125961A5

文献信息

• Poly-ADP ribose polymerase (PARP) inhibitors
  申请人：Mitobridge, Inc.

  公开号：US11034670B2

  公开（公告）日：2021-06-15

  The present invention is related to a pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a compound represented by the following structural formula: The present invention is also related a method of treating a subject with a disease which can be ameliorated by inhibition of poly(ADP-ribose)polymerase (PARP). The definitions of the variables are provided herein.

  本发明涉及一种药物组合物，该组合物包含一种药学上可接受的载体或稀释剂和一种由以下结构式表示的化合物： 本发明还涉及一种治疗患有可通过抑制聚（ADP-核糖）聚合酶（PARP）而改善的疾病的受试者的方法。本文提供了变量的定义。
• POLY-ADP RIBOSE POLYMERASE (PARP) INHIBITORS
  申请人：Mitobridge, Inc.

  公开号：EP3562822B1

  公开（公告）日：2021-03-10
• [EN] POLY-ADP RIBOSE POLYMERASE (PARP) INHIBITORS<br/>[FR] INHIBITEURS DE LA POLY-ADP-RIBOSE POLYMÉRASE (PARP)
  申请人：MITOBRIDGE INC

  公开号：WO2018125961A1

  公开（公告）日：2018-07-05

  The present invention is related to a pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a compound represented by the following structural formula: The present invention is also related a method of treating a subject with a disease which can be ameliorated by inhibition of poly(ADP-ribose)polymerase (PARP). The definitions of the variables are provided herein.